Follow The Filings

MDT Medtronic

Health Care, filed as MEDTRONIC PLC (SHS), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 4 managers in 2026 Q2, sold by 3

  • 3 Owners
  • #71
  • Max 3.0%
  • Master 0.12%
  • $44M
  • 2 add 1 reduce

In 2026 Q3 Murphy Pohlad and Kentucky Trust added to Medtronic, while David Katz trimmed.

Who owns this now

Largest portfolio weights among holders, up to 3.0% (David Katz, Matrix Asset Advisors). Not free-float ownership.

  1. David Katz Reduce 3.0%
  2. Murphy Pohlad Add 2.0%
  3. Kentucky Trust Co. Add 0.67%

Who owns MDT

Sorted by value, long equity only, as of 2026 Q3.

History
David Katz, Matrix Asset Advisors 3.0% Reduce −1.6% 426,624 $37M History
Murphy Pohlad, Murphy Pohlad Asset Management 2.0%, was 1.8% Add +3.2% 66,200 $5.7M History
Kentucky Trust Co., Kentucky Trust 0.67%, was 0.58% Add +0.4% 15,466 $1.3M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MDT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MDT insider trades
  • None no insider bought on the open market
  • $8.7M sold by 2 insiders outside a trading plan
  • $6M sold by 3 insiders under 10b5-1 plans
  1. Michael Marinaro EVP, Pres MedSurg and Americas
    Planned sale
    $1M 10,420 shares at $96.00 9% of stake
    Traded Oct 15 Filed Oct 16
    ↗
  2. Geoffrey Martha CEO
    Planned sale
    $4.8M 50,000 shares at $95.00 15% of stake
    Traded Oct 15 Filed Oct 16
    ↗
  3. Harry Skip Kiil EVP & President Cardiovascular
    Sale
    $139K 1,483 shares at $93.65 3.4% of stake
    Traded Sep 16 Filed Sep 17
    ↗
  4. Matthew R. Walter SVP, Chief HR Officer
    Planned sale
    $258K 3,102 shares at $83.15 8% of stake
    Traded Jul 8 Filed Jul 9
    ↗
  5. Harry Skip Kiil EVP & President Cardiovascular
    Sale
    $337K 4,189 shares at $80.44 10% of stake
    Traded Jun 8 Filed Jun 9
    ↗
  6. Harry Skip Kiil EVP & President Cardiovascular
    Sale
    $5.1M 52,524 shares at $97.71 62% of stake
    Traded Feb 19 Filed Feb 26
    ↗
  7. Gregory L Smith EVP Global Ops & Supply Chain
    Sale
    $3.1M 30,000 shares at $101.95 40% of stake
    Traded Nov 19, 2025 Filed Nov 21, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 29 share withholdings for taxes, 21 stock grants, 9 option exercises, 3 gifts, and 1 other transaction.

Congress

17 members of Congress traded MDT in the last three years: 11 buys and 25 sales. 16 members listed it in 2025 annual reports.

All Congress trades
  1. Kevin Hern R-OK-1Joint Sell $15K–$50K Aug 24 filed Sep 1
  2. Richard McCormick R-GA-7 Sell $1K–$15K Jul 30 filed Aug 14
  3. Julie Johnson D-TX-32Joint Partial sale $1K–$15K May 7, 2025 filed Aug 5
  4. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K May 15 filed Jun 8
  6. Kevin Hern R-OK-1Joint Sell $15K–$50K Mar 20 filed Apr 3

SEC filings

Recent issuer filings from EDGAR, 7 shown.

Filed Form Detail Links
8-K 5.02,5.07,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 9 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue $31.23B $32.36B $33.54B $36.36B
Gross profit * $20.51B $21.15B $21.9B $23.64B
Gross margin * 65.7% 65.3% 65.3% 65.0%
Net income $3.76B $3.68B $4.66B $4.8B
Net margin * 12.0% 11.4% 13.9% 13.2%

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $21.68B $21.94B $23.81B $24.79B
Total non-current assets * $69.27B $68.05B $67.87B $68.24B
Total assets $90.95B $89.98B $91.68B $93.03B
Total current liabilities $9.05B $10.79B $12.88B $11.66B
Total non-current liabilities * $30.23B $28.77B $30.54B $31.3B
Total equity $51.48B $50.21B $48.02B $49.46B

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations $6.04B $6.79B $7.04B $7.33B
Cash from investing -$3.49B -$2.37B -$1.94B -$2.93B
Cash from financing -$4.96B -$4.45B -$4.36B -$4.75B
Net change in cash -$2.17B -$0.259B $0.934B -$0.269B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.